Abstract
If genetic testing for breast and ovarian cancer predisposition is to become available within a public health care system there needs to be a rational and cost-effective approach to mutation analysis. We have screened for BRCA1 mutations in 230 women with breast cancer, all from the Wessex region of southern England, in order to establish the parameters on which to base a cost-effective regional mutation analysis strategy. Truncating mutations were detected in 10/155 (6.5%) consecutive cases selected only for diagnosis under the age of 40 (nine of these ten women had a strong family history of breast or ovarian cancer), 3/61 (4.9%) bilateral-breast cancer cases (all three mutations occurring among women for whom the first cancer was diagnosed under 40 years) and 8/30 (26.6%) breast cancer cases presenting to the genetics clinic (for whom a strong family history of breast and/or ovarian cancer was present). Ten different mutations were detected in 17 families, but three of these accounted for 10/17 (59%) of the families. The cost of screening the population for mutations in the entire BRCA1 gene is unacceptably high. However, the cost of screening a carefully selected patient cohort is low, the risk of misinterpretation much less and the potential clinical benefits clearer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eccles, D., Englefield, P., Soulby, M. et al. BRCA1 mutations in southern England. Br J Cancer 77, 2199–2203 (1998). https://doi.org/10.1038/bjc.1998.366
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.366
This article is cited by
-
Genetic testing in the European Union: does economic evaluation matter?
The European Journal of Health Economics (2012)
-
Identification of personal risk of breast cancer: genetics
Breast Cancer Research (2008)
-
A family history of breast cancer will not predict female early onset breast cancer in a population-based setting
BMC Cancer (2008)
-
A novel duplication polymorphism in the FANCApromoter and its association with breast and ovarian cancer
BMC Cancer (2005)
-
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
Breast Cancer Research (2004)